hurricanedaddy30 Mar 2019 11:34
RNS 5.4.19
The gross proceeds to Xenetic from the registered direct offering are expected
to be approximately $3.1 million before deducting placement agent fees and
other offering expenses. The offering is expected to close on or about March
7, 2019, subject to the satisfaction of customary closing conditions.
RNS 4.3.19
Xenetic announced today its agreement to acquire the novel CAR T ("Chimeric Antigen
Receptor T Cell") platform technology, called "XCART," a proximity-based
screening platform capable of identifying CAR constructs that can target
patient-specific tumor neoantigens, with a demonstrated proof of mechanism in
B-cell Non-Hodgkin lymphomas. The XCART technology, developed by The Scripps
Research Institute ("Scripps") in collaboration with the Shemyakin-Ovchinnikov
Institute of Bioorganic Chemistry, is believed to have the potential to
significantly enhance the safety and efficacy of cell therapy for B-cell
lymphomas by generating patient- and tumor-specific CAR T cells. The
acquisition is subject to conditions typical for a transaction of this kind,
including appropriate stockholder approvals, and is expected to close in the
first half of 2019.
"This acquisition is a transformative step in the strategic evolution of
Xenetic," commented Jeffrey Eisenberg, Chief Executive Officer of Xenetic.
Funding now from placings rather than 'partners' !